Mixed
Empagliflozin (10-25 mg daily) reduces the risk of major adverse cardiovascular events (MACE), cardiovascular death, all-cause mortality, and hospitalization for heart failure in patients with type 2 diabetes at high cardiovascular risk.
If you have type 2 diabetes and established heart disease, adding empagliflozin (10-25 mg daily) to your standard care significantly lowers your risk of heart attack, stroke, heart failure hospitalization, and death from any cause. While you may experience an increased risk of genital infections, the cardiovascular benefits are substantial and well-documented in this large trial.
Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care.
Why this rating
Large-scale, randomized, double-blind, placebo-controlled trial (EMPA-REG OUTCOME) with adjudicated outcomes.
Source
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al. · New England Journal of Medicine · 2015
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →